Robert M. Day

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Kim Papp, Kristian Reich, Craig L. Leonardi et al. · Journal of the American Academy of Dermatology · 2015 · 669 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

Kim Papp, Jennifer Clay Cather, Les Rosoph et al. · The Lancet · 2012 · 280 citations

Medicine, Dermatology, Pharmacotherapy +6

Two considerations for patients with psoriasis and their clinicians:

Gerald G. Krueger, Steven R. Feldman, Charles Camisa et al. · Journal of the American Academy of Dermatology · 2000 · 231 citations

Medicine, Clinical Sciences, Dermatology +6

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)

Kristian Reich, Melinda Gooderham, L. Green et al. · Journal of the European Academy of Dermatology and Venereology · 2016 · 198 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Jeffrey Crowley, Diamant Thaçi, P. Joly et al. · Journal of the American Academy of Dermatology · 2017 · 192 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16